Your browser doesn't support javascript.
Development of an in-house quantitative ELISA for the evaluation of different Covid-19 vaccines in humans.
Gdoura, Mariem; Ghaloum, Fatma Ben; Hamida, Meriem Ben; Chamsa, Wafa; Triki, Henda; Bahloul, Chokri.
  • Gdoura M; Laboratory of Clinical Virology, Institut Pasteur de Tunis, Tunis, Tunisia.
  • Ghaloum FB; Research Laboratory « Virus, Vector and Hosts ¼ LR20IPT02, Tunis, Tunisia.
  • Hamida MB; Faculty of Pharmacy of Monastir, University of Monastir, Monastir, Tunisia.
  • Chamsa W; Vaccinologie et Développement Biotechnologique, LR11IPT01 Microbiologie Moléculaire, Institut Pasteur de Tunis, Université de Tunis El Manar, 13, Place Pasteur, BP 74, 1002, Tunis-Belvedere, Tunisia.
  • Triki H; Laboratory of Clinical Virology, Institut Pasteur de Tunis, Tunis, Tunisia.
  • Bahloul C; Laboratory of Clinical Virology, Institut Pasteur de Tunis, Tunis, Tunisia.
Sci Rep ; 12(1): 11298, 2022 07 04.
Article in English | MEDLINE | ID: covidwho-2028705
ABSTRACT
Reliable serological assays are needed to understand the real impact of COVID-19. In order to compare the efficiency of different COVID-19 vaccines used in the National Vaccination Program in Tunisia, we have developed a quantitative in-house ELISA. The ELISA is based on the ectodomain of the SARS-CoV-2 Spike Baculovirus recombinant protein. We used a panel of 145 COVID-19 RT-PCR positive serum samples and 116 pre-pandemic serum samples as a negative panel. The validation was carried out by comparison to four commercial techniques (Vidas SARS-CoV-2 IgG anti-RBD Biomérieux, Elecsys Anti-Nucleocapsid of SARS-CoV-2 Roche, cPass GenScript and the quantitative Elecsys Anti-RBD of SARS-CoV-2, Roche). For the evaluation of the National Vaccination campaign, we have included 115 recipients who received one of the approved vaccines. The qualitative performances of the developed ELISA gave 96% sensitivity, 97.5% specificity and 0.968 accuracy. For the evaluation of the different brand of vaccines in recipients not previously infected with SARS-CoV-2, it seems that mRNA vaccine of Pfizer/BioNTech has shown a higher efficacy compared to inactivated virus vaccines. COVID-19 convalescent individuals have generated poor antibody responses. Nevertheless, when they are vaccinated with any brand of the COVID-19 vaccines, many of them mounted an exponential increase of the induced immune responses, qualified as a "hybrid vigor immunity". Our developed in-house ELISA seems to be very efficient in evaluating the effectiveness of anti-COVID-19 vaccination. Platforms based on mRNA vaccine are better performing than those based on inactivated virus.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / COVID-19 Type of study: Experimental Studies / Prognostic study / Qualitative research Topics: Vaccines Limits: Humans Language: English Journal: Sci Rep Year: 2022 Document Type: Article Affiliation country: S41598-022-15378-1

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Viral Vaccines / COVID-19 Type of study: Experimental Studies / Prognostic study / Qualitative research Topics: Vaccines Limits: Humans Language: English Journal: Sci Rep Year: 2022 Document Type: Article Affiliation country: S41598-022-15378-1